{"id":5398,"date":"2025-12-11T07:03:58","date_gmt":"2025-12-11T07:03:58","guid":{"rendered":"https:\/\/regenerative-thermal-oxidizers.com\/?p=5398"},"modified":"2025-12-11T07:03:58","modified_gmt":"2025-12-11T07:03:58","slug":"rto-for-sterile-api-crystallization-and-drying-exhaust-treatment","status":"publish","type":"post","link":"https:\/\/regenerative-thermal-oxidizers.com\/bg\/rto-for-sterile-api-crystallization-and-drying-exhaust-treatment\/","title":{"rendered":"RTO for Sterile API Crystallization and Drying Exhaust Treatment"},"content":{"rendered":"
\n
\n

RTO for Sterile API Crystallization and Drying Exhaust Treatment<\/h1>\n

How our rotor concentrator plus RTO system efficiently handles acetonitrile and DMF emissions from sterile API crystallization and drying\u2014while achieving >99% DRE and maximizing energy efficiency in real-world applications.<\/p>\n<\/div>\n

\n

When it comes to sterile API crystallization and drying, you know the drill. Acetonitrile (ACN) and dimethylformamide (DMF) are common byproducts of these processes, which can pose significant challenges for air pollution control. We’ve seen facilities struggle with variable concentrations ranging from 50\u2013500 mg\/Nm\u00b3. These levels can easily exceed safety limits if not properly managed. And let\u2019s not forget about the regulatory pressure. Under US EPA guidelines, emissions must be controlled to meet stringent destruction removal efficiencies (DRE).<\/p>\n

The challenge isn\u2019t just about hitting DRE targets\u2014it\u2019s about doing so while managing concentration spikes and maintaining safety. Most standard RTO systems aren\u2019t equipped to handle these peaks without risking an explosion. The trick? A rotor concentrator coupled with a regenerative thermal oxidizer (RTO) that provides continuous operation and enhanced heat recovery insulation to maintain high efficiency even under fluctuating conditions.<\/p>\n

Understanding Your Process Emissions<\/h2>\n

Each step in the sterile API crystallization and drying process emits different compounds:<\/p>\n

\n\n\n\n\n\n\n\n
Process Step<\/th>\nKey VOC Components<\/th>\nTypical Flow & Concentration<\/th>\nUnique Challenge<\/th>\n<\/tr>\n<\/thead>\n
Crystallization<\/td>\nAcetonitrile, DMF<\/td>\n20k\u201350k Nm\u00b3\/h | 50\u2013200 mg\/Nm\u00b3<\/td>\nVariable concentration affects DRE<\/td>\n<\/tr>\n
Drying<\/td>\nAcetonitrile, water vapor<\/td>\nVariable flow | peaks up to 500 mg\/Nm\u00b3<\/td>\nSudden VOC spikes require rapid dilution<\/td>\n<\/tr>\n
Cooling Phase<\/td>\nLow VOC content<\/td>\nReduced airflow | low concentration<\/td>\nEnergy-efficient operation needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

VOC concentrations can vary significantly depending on the phase of the process. During crystallization, the exhaust stream contains significant amounts of acetonitrile and DMF, both of which are highly volatile solvents requiring efficient capture to prevent environmental release. Our solution? A rotor concentrator coupled with an RTO designed to optimize heat recovery and minimize fuel consumption. This approach ensures consistent performance even during peak loads, reducing fuel use and enhancing safety.<\/p>\n

Navigating Regulatory Compliance Across Continents<\/h2>\n

Compliance isn’t one-size-fits-all. Teva in the USA has to adhere to strict US EPA guidelines, including a minimum DRE of 99% for all HAPs. Meanwhile, Recordati in Italy operates under TA-Luft regulations, which set limits on total organic carbon (TOC) emissions. In Indonesia, Kalbe follows local regulations that cap NMHC at 10 mg\/Nm\u00b3 for new installations. And then there’s China, where GB 31572-2015 mandates benzene levels below 1 mg\/Nm\u00b3\u2014a benchmark many plants struggle to meet consistently.<\/p>\n

We worked with a facility in Egypt where local regulations required biannual stack tests. Their previous system barely met standards, leading to constant anxiety about potential fines. By switching to our regenerative thermal oxidizer with integrated LEL monitoring and advanced thermal recovery, they achieved consistent compliance\u2014without sacrificing operational flexibility.<\/p>\n

Why Standard Two-Bed RTOs Fall Short in Pharmaceutical Applications<\/h2>\n

We\u2019ve seen numerous failures firsthand. Common issues?<\/p>\n